These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 23172668

  • 1. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
    Wang ZL, Fan ZQ, Jiang HD, Qu JM.
    Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
    Pan H, Jiang T, Cheng N, Wang Q, Ren S, Li X, Zhao C, Zhang L, Cai W, Zhou C.
    Oncotarget; 2016 Aug 02; 7(31):49948-49960. PubMed ID: 27409677
    [Abstract] [Full Text] [Related]

  • 4. Inactivation of M2 AChR/NF-κB signaling axis reverses epithelial-mesenchymal transition (EMT) and suppresses migration and invasion in non-small cell lung cancer (NSCLC).
    Zhao Q, Yue J, Zhang C, Gu X, Chen H, Xu L.
    Oncotarget; 2015 Oct 06; 6(30):29335-46. PubMed ID: 26336823
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prostaglandin E2 is a potent inhibitor of epithelial-to-mesenchymal transition: interaction with hepatocyte growth factor.
    Zhang A, Wang MH, Dong Z, Yang T.
    Am J Physiol Renal Physiol; 2006 Dec 06; 291(6):F1323-31. PubMed ID: 16868306
    [Abstract] [Full Text] [Related]

  • 16. Celecoxib attenuates hepatic cirrhosis through inhibition of epithelial-to-mesenchymal transition of hepatocytes.
    Wen SL, Gao JH, Yang WJ, Lu YY, Tong H, Huang ZY, Liu ZX, Tang CW.
    J Gastroenterol Hepatol; 2014 Nov 06; 29(11):1932-42. PubMed ID: 24909904
    [Abstract] [Full Text] [Related]

  • 17. COX-2 inhibition and lung cancer.
    Sandler AB, Dubinett SM.
    Semin Oncol; 2004 Apr 06; 31(2 Suppl 7):45-52. PubMed ID: 15179623
    [Abstract] [Full Text] [Related]

  • 18. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1.
    Cha BK, Kim YS, Hwang KE, Cho KH, Oh SH, Kim BR, Jun HY, Yoon KH, Jeong ET, Kim HR.
    Oncotarget; 2016 Aug 30; 7(35):57213-57227. PubMed ID: 27528025
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis.
    Wang H, Zhang H, Tang L, Chen H, Wu C, Zhao M, Yang Y, Chen X, Liu G.
    Toxicology; 2013 Jan 07; 303():139-46. PubMed ID: 23146760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.